BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32058605)

  • 1. Chronic lymphocytic leukemia and secondary hematological malignancies: A nation-wide cancer registry study.
    Lenartova A; Johannesen TB; Tjønnfjord GE
    Eur J Haematol; 2020 Jun; 104(6):546-553. PubMed ID: 32058605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.
    Mishra R; Dima D; Kumar SA; Mian A; Taneja A; Karna R; Caimi PF; Hill BT; Dean R; Jagadeesh D
    Hematol Oncol; 2023 Dec; 41(5):884-893. PubMed ID: 37309225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway.
    Lenartova A; Randen U; Johannesen TB; Tjønnfjord GE
    Cancer Epidemiol; 2019 Jun; 60():128-133. PubMed ID: 30986631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.
    Chang TW; Weaver AL; Shanafelt TD; Habermann TM; Wriston CC; Cerhan JR; Call TG; Brewer JD
    Int J Dermatol; 2017 Nov; 56(11):1125-1129. PubMed ID: 28685851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data.
    Lenartova A; Johannesen TB; Tjønnfjord GE
    Cancer Med; 2016 Dec; 5(12):3588-3595. PubMed ID: 27925456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
    Morton LM; Curtis RE; Linet MS; Bluhm EC; Tucker MA; Caporaso N; Ries LA; Fraumeni JF
    J Clin Oncol; 2010 Nov; 28(33):4935-44. PubMed ID: 20940199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    da Cunha-Bang C; Rostgaard K; Andersen MA; Rotbain EC; Grønbaek K; Frederiksen H; Niemann CU; Hjalgrim H
    Br J Haematol; 2021 Apr; 193(2):339-345. PubMed ID: 33570184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
    Robertson LE; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating MJ
    Leukemia; 1994 Dec; 8(12):2047-51. PubMed ID: 7807993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
    Niparuck P; Kanoksil W; Chuncharunee S; Boonsakan P; Ungkanont A; Angchaisuksiri P; Karntisaviwat K; Apilugsanachit A; Rerkamnuatchoke B; Jootar S; Nitiyanant P; Atichartakarn V
    Leuk Lymphoma; 2010 Nov; 51(11):2120-5. PubMed ID: 20846095
    [No Abstract]   [Full Text] [Related]  

  • 11. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
    Tietsche de Moraes Hungria V; Chiattone C; Pavlovsky M; Abenoza LM; Agreda GP; Armenta J; Arrais C; Avendaño Flores O; Barroso F; Basquiera AL; Cao C; Cugliari MS; Enrico A; Foggliatto LM; Galvez KM; Gomez D; Gomez A; de Iracema D; Farias D; Lopez L; Mantilla WA; Martínez D; Mela MJ; Miguel CE; Ovilla R; Palmer L; Pavlovsky C; Ramos C; Remaggi G; Santucci R; Schusterschitz S; Sossa CL; Tuna-Aguilar E; Vela J; Santos T; de la Mora O; Machnicki G; Fernandez M; Barreyro P
    J Glob Oncol; 2019 Nov; 5():1-19. PubMed ID: 31774711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
    Harrop S; Polliack A; Tam CS
    Leuk Lymphoma; 2021 Apr; 62(4):771-778. PubMed ID: 33222561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA.
    Ailawadhi S; Ravelo A; Ng CD; Shah B; Lamarre N; Wang R; Eakle K; Biondo JM
    J Comp Eff Res; 2024 Feb; 13(2):e230119. PubMed ID: 38294335
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases.
    Mauro FR; Foa R; Giannarelli D; Cordone I; Crescenzi S; Pescarmona E; Sala R; Cerretti R; Mandelli F
    Blood; 1999 Jul; 94(2):448-54. PubMed ID: 10397712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.
    Kumar V; Ailawadhi S; Bojanini L; Mehta A; Biswas S; Sher T; Roy V; Vishnu P; Marin-Acevedo J; Alegria VR; Paulus A; Aulakh S; Iqbal M; Manochakian R; Tan W; Chanan-Khan A; Ailawadhi M
    Blood Cancer J; 2019 Sep; 9(10):75. PubMed ID: 31570695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
    Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
    BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.
    Falchi L; Vitale C; Keating MJ; Lerner S; Wang X; Elhor Gbito KY; Strom S; Wierda WG; Ferrajoli A
    Ann Oncol; 2016 Jun; 27(6):1100-1106. PubMed ID: 26912560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study.
    Beiggi S; Johnston JB; Seftel MD; Pitz MW; Kumar R; Banerji V; Griffith EJ; Gibson SB
    Br J Cancer; 2013 Sep; 109(5):1287-90. PubMed ID: 23860531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
    Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
    Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience.
    Chavez JC; Dalia S; Sandoval-Sus J; Kharfan-Dabaja MA; Al-Ali N; Komrokji R; Padron E; Corrales-Yepez G; Rock-Klotz J; Pinilla-Ibarz J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S14-8. PubMed ID: 26297266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.